Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerJulie R. Brahmer, Jon M. Wigginton, Scott S. Tykodi et al.|New England Journal of Medicine|2012Cited by 8k
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)Poulam M. Patel, Alan Spatz, Caroline Robert et al.|European Journal of Cancer|2011Cited by 210